Adjuvant therapy for stage III colon cancer
Author Information
Author(s): Schippinger W, Jagoditsch M, Sorré C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger H J, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R
Primary Institution: Austrian Breast and Colorectal Cancer Study Group
Hypothesis
Does the addition of levamisole or interferon alfa to 5-FU improve outcomes in stage III colon cancer?
Conclusion
The addition of levamisole to adjuvant 5-FU worsened the prognosis for patients with stage III colon cancer, while interferon alfa had no significant impact on survival.
Supporting Evidence
- Patients treated with levamisole had a significantly higher risk of relapse.
- Levamisole treatment was associated with a higher risk of death compared to no levamisole.
- Interferon alfa did not show a significant impact on overall survival.
Takeaway
This study found that adding levamisole to a common cancer treatment made things worse for patients, while another drug, interferon, didn't help at all.
Methodology
Patients were randomly assigned to one of four treatment arms involving 5-FU with or without levamisole and interferon alfa.
Potential Biases
There may be risks of bias due to the multicenter design and patient selection criteria.
Limitations
The study was limited by the potential for bias in treatment adherence and the generalizability of results to broader populations.
Participant Demographics
Patients aged 18 to 80 with histologically proven stage III colon cancer.
Statistical Information
P-Value
P=0.0028 for relapse risk with levamisole; P=0.0027 for death risk with levamisole.
Confidence Interval
95% CI 1.135–1.856 for relapse; 95% CI 1.150–1.973 for death.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website